Multivariable logistic regression in the primary cohort of hospitalized patients with comorbid T2DM and HTN or CHD plus T2DM and HTN, using short-term SGLT2 inhibitor use (vs. non-use) as the dependent variable, showed that compared to non-users, SGLT2 inhibitor users had 0.528 times lower MRV(Venular)C risk (P < 0.001, 95% CI: 0.426–0.654) but 138,537.642 times higher AVR1.5–2.0PD risk (P = 0.003, 95% CI: 55.646–>100), detailed in Supplementary Table S23 and Figure 4. This evidence concerns the gene SLC5A2 and coronary artery disorder.